TY - JOUR
T1 - PI3K inhibitors as potential therapeutics for autoimmune disease
AU - Ball, Jennifer
AU - Archer, Sophie
AU - Ward, Stephen
PY - 2014/8
Y1 - 2014/8
N2 - Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide 3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Recent studies into the function of selective PI3K inhibitors in vitro and in vivo have yielded encouraging results, allowing progression into the clinic. Here, we review their recent progress across a range of autoimmune diseases.
AB - Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide 3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Recent studies into the function of selective PI3K inhibitors in vitro and in vivo have yielded encouraging results, allowing progression into the clinic. Here, we review their recent progress across a range of autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=84899467745&partnerID=8YFLogxK
UR - http://dx.doi.org/10.1016/j.drudis.2014.04.002
U2 - 10.1016/j.drudis.2014.04.002
DO - 10.1016/j.drudis.2014.04.002
M3 - Article
SN - 1359-6446
VL - 19
SP - 1195
EP - 1199
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -
